Federal Appeals Court Blocks Trump-Era Hospital Drug Rebate Plan 
China’s AI Sector Pushes to Close U.S. Tech Gap Amid Chipmaking Challenges 
AustralianSuper Backs BlueScope Steel’s Rejection of $9 Billion Takeover Bid 
Elon Musk Says X Will Open-Source Its Algorithm Amid EU Scrutiny 
Stellantis to End Plug-In Hybrid Sales in the U.S. as Demand Shifts Toward Traditional Hybrids 
Walmart to Join Nasdaq-100 Index as It Replaces AstraZeneca Following Exchange Move 
Hanwha Ocean Shares Rise on Plans to Expand U.S. Shipbuilding Capacity 
Samsung Forecasts Strong Q4 Profit on AI-Driven Memory Chip Boom 
Trump Calls for 10% Credit Card Interest Rate Cap Starting 2026 
FCC Exempts Select Foreign-Made Drones From U.S. Import Ban Until 2026 
Ford Targets Level 3 Autonomous Driving by 2028 with New EV Platform and AI Innovations 
FTC Blocks Edwards Lifesciences’ JenaValve Acquisition in Major Antitrust Ruling 
GM Takes $6 Billion EV Write-Down as Electric Vehicle Demand Slows in the U.S. 
Chevron Seeks Expanded U.S. License to Boost Venezuelan Oil Exports Amid Sanctions Talks 
EU Orders Elon Musk’s X to Preserve Grok AI Data Amid Probe Into Illegal Content 
BlueScope Steel Shares Slip After Board Rejects A$13.2 Billion Takeover Bid 
REDWOOD CITY, Calif., Oct. 24, 2017 -- OncoMed Pharmaceuticals, Inc. (Nasdaq:OMED), a clinical-stage biopharmaceutical company focused on discovering and developing novel anti-cancer therapeutics, today announced that the Company will report third quarter 2017 financial results and operational highlights on Thursday November 2nd, 2017. OncoMed management will host a conference call and webcast at 4:30 p.m. Eastern Time (ET) / 1:30 p.m. Pacific Time (PT).
Analysts and investors can participate in the conference call by dialing 1-(855) 420-0692 (domestic) and 1-(484) 756-4194 (international) using the conference ID# 4699289. The webcast of the conference call can be accessed live on the Investor Relations section of the OncoMed website, http://www.oncomed.com, and will be available for replay through February 28th, 2018.
An audio replay of the conference call can be accessed by dialing 1-(855) 859-2056 (domestic) or 1-(404) 537-3406 (international) utilizing the conference ID number listed above.
About OncoMed Pharmaceuticals
OncoMed Pharmaceuticals is a clinical-stage biopharmaceutical company focused on discovering and developing novel anti-cancer therapeutics. OncoMed has internally discovered a broad pipeline of investigational drugs intended to address the fundamental biology driving cancer's growth, resistance, recurrence and metastasis. Navicixizumab (anti-DLL4/VEGF bispecific, OMP-305B83), rosmantuzumab (anti-RSPO3, OMP-131R10) and anti-TIGIT (OMP-313M32) are part of the company's strategic alliances with Celgene Corporation. OncoMed is independently developing GITRL-Fc (OMP-336B11), as well as continuing to pursue new drug discovery research. The Company is also evaluating potential partnering opportunities for vantictumab (anti-Fzd, OMP-18R5) and ipafricept (Fzd8-Fc, OMP-54F28). For further information about OncoMed Pharmaceuticals, please see www.oncomed.com.
Investor Relations Contact
Peter Rahmer
Trout Group
[email protected]
(646) 378-2973
Mike Zanoni
Trout Group
[email protected]
(646) 378-2924
